C4 Therapeutics, Inc.

C4 Therapeutics presented new biomarker data from its Phase 1 clinical trial of cemsidomide in combination with dexamethasone and preliminary biomarker data from its Phase 1b trial of cemsidomide in combination with elranatamab. The data demonstrate cemsidomide's immunomodulatory activity, showing robust T-cell activation and expansion, and prevention of T-cell exhaustion. The 75 µg dose level in the Phase 1b trial was declared safe, and the trial is advancing to dose escalation and expansion cohorts. Data from all cohorts are expected in mid-2027.

C4 Therapeutics announced a new collaboration and license agreement with Roche to develop degrader-antibody conjugates (DACs) for oncology targets. The agreement includes an upfront payment of $20.0 million and potential milestone payments exceeding $1.0 billion. For the six months ended June 30, 2026, the company reported a net loss of $48.8 million, an improvement from $52.3 million in the prior year period. C4 Therapeutics also confirmed its cash, cash equivalents, and marketable securities of $300.4 million are sufficient to fund operations for at least the next twelve months.

C4 Therapeutics reported a net loss of $23.6 million, or $0.18 per share, for Q2 2026, an improvement from a net loss of $26.0 million, or $0.37 per share, in Q2 2025. Revenue for the quarter was $6.6 million, slightly up from $6.5 million year-over-year. The company's cash, cash equivalents, and marketable securities stood at $300.4 million as of June 30, 2026, providing a cash runway until the end of 2028. Key clinical programs for cemsidomide, including the Phase 2 MOMENTUM trial and Phase 1b combination trials, remain on track for data readouts in 2027, alongside a new collaboration with Roche and $33.5 million raised through its ATM program.

C4 Therapeutics, Inc. held its Annual Meeting of Stockholders on June 24, 2026. Stockholders elected Andrew J. Hirsch, Stephen Fawell, Ph.D., and Utpal Koppikar as Class III directors. They also approved the non-binding advisory vote on executive compensation and ratified KPMG LLP as the independent registered public accounting firm for 2026. Additionally, an amendment to the Company's 2020 Stock Option and Incentive Plan was approved, modifying the evergreen provision to include outstanding pre-funded warrants.

C4 Therapeutics, Inc. announced the presentation of updated Phase 1 data for its investigational drug cemsidomide in combination with dexamethasone for relapsed/refractory multiple myeloma (RRMM) at the European Hematology Association (EHA) 2026 Congress. The data, with a cutoff of February 27, 2026, showed a 53% overall response rate (ORR) at the recommended Phase 2 dose (RP2D) of 100 µg, with responses deepening over time and some achieving stringent complete response (sCR) and minimal residual disease (MRD) negativity. The combination was generally well-tolerated. The company is advancing cemsidomide through further clinical trials, including the Phase 2 MOMENTUM trial in 4L+ MM and a Phase 1b trial with elranatamab, and is also exploring a new discovery strategy in INN diseases.

C4 Therapeutics presented positive Phase 1 data for cemsidomide, an IKZF1/3 degrader, in relapsed/refractory multiple myeloma (RRMM) at EHA 2026. At the 100 µg Recommended Phase 2 Dose, cemsidomide achieved a 53% Overall Response Rate, including complete responses and minimal residual disease negative status. The drug demonstrated a differentiated safety profile and was well tolerated, supporting its potential as a foundational therapy for RRMM. The company plans further development, including a Phase 2 trial and a combination study with elranatamab.

C4 Therapeutics, Inc. announced that its management will participate in three upcoming healthcare conferences. These include a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit on May 26, 2026, and a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. Additionally, management will hold 1x1 meetings at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. Live webcasts and archived replays will be available on the company's investor relations website.

C4 Therapeutics announced that its Board's Organization, Leadership and Compensation Committee approved an inducement grant of non-qualified stock options for 85,480 shares to a new employee on May 18, 2026. This grant serves as a material inducement for the individual's employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price equal to the closing stock price on the grant date and will vest over four years, with 25% vesting after the first year and the remainder monthly thereafter, contingent on continued employment.

C4 Therapeutics announced a change in its principal accounting officer role. Mark Mossler will no longer serve as Chief Accounting Officer, effective May 15, 2026, a departure not due to any disagreements. Kendra R. Adams, the company's Chief Financial Officer, Head of Corporate Affairs, and Treasurer, has been designated as the new principal accounting officer, effective the same date. Ms. Adams will not receive additional compensation for this expanded role.

C4 Therapeutics reported a net loss of $25.1 million for the first quarter of 2026, an improvement from the $26.3 million net loss in the same period last year. Revenue from collaboration agreements was $6.15 million, down from $7.24 million year-over-year. The company ended the quarter with $268.3 million in cash, cash equivalents, and marketable securities, which is expected to fund operations for at least the next twelve months.